1351
disorders were excluded by only entering men with fasting plasma cholesterol concentrations between 4-0 and 80 mmol/1 and triglyceride concentrations below 40 mmol/1. We compared these CAD patients with a group of 352, 35-year-old healthy Dutch males, randomly selected from a much larger group2 and with the same cut-offs for plasma cholesterol and triglyceride. Although there is a tendency for a higher frequency of the s4 allele in the younger men with angiographically verified CAD, this difference is not significant; nor is the s4 frequency increased in the CAD group as a whole (table). Our results argue against the involvement of apo E polymorphism in determining the risk for CAD. Department of Fibrinolysis and Proteolysis, IVVO-TNO Gaubius Laboratory, 40
60
mg/day
mg/day
Lovastatin Dose
Effect of
and apoE phenotype response to lovastatin in HFH.
Results
as
sex
on
LDL-cholesterol
% reduction in LDL-cholesterol (mean and SEM)
PO Box 430, 2300 AK Leiden, Netherlands, Department of Internal Medicine III and Biochemistry, Erasmus University Rotterdam; and Interuniversity Cardiology Institute, Netherlands (ICIN), Utrecht
P. DE KNIJFF H. JANSEN K. I. LIE L. M. HAVEKES
Statistical significance by one-way ANOVA. 1. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and
HFH by several mechanisms, including exacerbation of the
low-density lipoprotein (LDL) cholesterol or lipoprotein(a) increase in these patients or, potentially, by reducing the efficacy of diet and drug therapy. We have done an expandedz analysis of the influence of sex and apo E phenotype on lipid-lowering in response to lovastatin in 208 adults with HFH (figure). At the 80 mg per day dose the reduction of LDL cholesterol was greater in women (41-7 [SD 106]%; This n=84) than in men (34-3 [14.8]%; n=60; p
disorders were excluded by only entering men with fasting plasma cholesterol concentrations between 4-0 and 80 mmol/1 and triglyceride concentrations below 40 mmol/1. We compared these CAD patients with a group of 352, 35-year-old healthy Dutch males, randomly selected from a much larger group2 and with the same cut-offs for plasma cholesterol and triglyceride. Although there is a tendency for a higher frequency of the s4 allele in the younger men with angiographically verified CAD, this difference is not significant; nor is the s4 frequency increased in the CAD group as a whole (table). Our results argue against the involvement of apo E polymorphism in determining the risk for CAD. Department of Fibrinolysis and Proteolysis, IVVO-TNO Gaubius Laboratory, 40
60
mg/day
mg/day
Lovastatin Dose
Effect of
and apoE phenotype response to lovastatin in HFH.
Results
as
sex
on
LDL-cholesterol
% reduction in LDL-cholesterol (mean and SEM)
PO Box 430, 2300 AK Leiden, Netherlands, Department of Internal Medicine III and Biochemistry, Erasmus University Rotterdam; and Interuniversity Cardiology Institute, Netherlands (ICIN), Utrecht
P. DE KNIJFF H. JANSEN K. I. LIE L. M. HAVEKES
Statistical significance by one-way ANOVA. 1. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and
HFH by several mechanisms, including exacerbation of the
low-density lipoprotein (LDL) cholesterol or lipoprotein(a) increase in these patients or, potentially, by reducing the efficacy of diet and drug therapy. We have done an expandedz analysis of the influence of sex and apo E phenotype on lipid-lowering in response to lovastatin in 208 adults with HFH (figure). At the 80 mg per day dose the reduction of LDL cholesterol was greater in women (41-7 [SD 106]%; This n=84) than in men (34-3 [14.8]%; n=60; p
